Regulus Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph P. Hagan
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4224 Campus Point Court San Diego CA United States of America 92121
- IPO Date
- Oct 9, 2012
- CIK
- 0001505512
- Website
- regulusrx.com
- Similar Companies
- Business
- Regulus Therapeutics Inc. (RGLS) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA-targeted oligonucleotide therapeutics for orphan kidney diseases, including autosomal dominant polycystic kidney disease (ADPKD). The company develops single-stranded anti-miR oligonucleotides designed to inhibit dysregulated microRNA targets, such as miR-17; its lead product candidate, farabursen (RGLS8429), is an investigational next-generation oligonucleotide with preferential kidney exposure aimed at reducing cyst growth, total kidney volume, and disease progression in ADPKD patients, supported by positive Phase 1b multiple-ascending dose trial data showing mechanistic dose response via urinary polycystin biomarkers and height-adjusted total kidney volume (htTKV) stabilization. Regulus maintains a preclinical pipeline leveraging target organ-selective delivery strategies for renal, hepatic, and central nervous system indications. Founded in 2007 as a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals (now Ionis), the company is headquartered in San Diego, California, and primarily operates in the United States within the biotechnology sector, targeting patients with genetically based rare diseases. In a transformative development, Novartis AG completed its acquisition of Regulus on June 25, 2025, making Regulus an indirect wholly owned subsidiary following a tender offer at $7.00 per share plus a contingent value right (CVR) for an additional $7.00 upon farabursen regulatory approval milestone achievement, with total potential consideration of approximately $1.7 billion; the deal, announced April 30, 2025, enhances Novartis' renal disease portfolio and advances farabursen's path toward a Phase 3 pivotal trial aligned with FDA End-of-Phase 1 feedback. Prior to the acquisition, Regulus reported successful completion of farabursen's Phase 1b trial in March 2025, confirming safety, tolerability, and efficacy signals consistent across patient subgroups.
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
Novartis completes acquisition of Regulus Therapeutics
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Should You Buy Regulus (RGLS) After Golden Cross?
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
4 Best Stocks To Buy Under $5
What Makes Regulus (RGLS) a New Buy Stock
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates